CERT · CIK 1827090
What Certara, Inc. told the SEC could break it.
Certara's most distinctive risk is its dependence on a functioning U.S. research-and-regulatory ecosystem. Because its software and services support drug development, federal workforce reductions and policy shifts across the FDA, NIH and other agencies could delay regulatory guidance, inspections and reviews — and disrupt the basic research and clinical testing that generate demand for its products. Beyond that, its register is more routine: about 31% of 2025 revenue was earned in foreign currencies (mainly the pound, euro and yen) with no FX hedges in place, and it carries a first-lien secured credit agreement with a leverage covenant that applies when its revolver is heavily drawn.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- U.S. government / FDA / NIH workforce reductions disrupting biopharma R&D and regulatory reviewmedium
Federal workforce reductions and policy changes across HHS, FDA, NIH, NSF, and CDC could delay or reduce regulatory guidance, inspections, and reviews and disrupt the basic research and clinical testing that drive demand for Certara's drug-development software and services.
“These workforce disruptions could lead to delays or reduced availability of regulatory guidance, inspections, and review activities.”
SEC filing →As of 2026
Currency (FX)
- foreign-currency revenue (31%; GBP, EUR, JPY)low
31% of 2025 revenue was transacted in foreign currencies (mainly British Pound, Euro, and Japanese Yen), exposing results to translation and transaction FX risk; Certara held no FX forward contracts at year-end.
“During the years ended December 31, 2025 and 2024, 31% and 28%, respectively, of our revenues were transacted in foreign currencies, the majority of which included the British Pound Sterling, the 32 Table of Contents Euro and Japanese Yen.”
SEC filing →As of 2026
Liquidity & debt
- secured first-lien Credit Agreement with leverage covenantlow
Borrowings under the Credit Agreement are secured on a first-lien basis by substantially all assets and subject to restrictive covenants, including a first-lien leverage ratio that must be maintained when revolver usage exceeds a threshold.
“In addition, the restrictive covenants in our Credit Agreement require us to maintain a specified first lien leverage ratio when a certain percentage of our revolving credit facility commitments are borrowed and outstanding as of the end of each fiscal quarter.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch